4.30pm – 5pm GMT, 6 November 2024 ‐ 30 mins
Panel discussion
Session Three: Data, digital technologies and real-world evidence
Session Chair: Kathy Williams, Head of Global Regulatory Policy and Intelligence, AstraZeneca, and Vice-Chair, BIA Regulatory Affairs Advisory Committee
Executive Director Regulatory Policy, Intelligence & Regional Strategy, AstraZeneca
Regulatory Chapter Lead & Regulatory Science Lead , Roche Pharmaceuticals
Chief Safety Officer, MHRA
Dr Cave joined the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2021 as the Chief Safety Officer with responsibility for the safety of medicines and devices in the UK. She holds a BSc Honours degree and PhD from the University of London and has significant academic research and regulatory experience, the latter at both the European Medicines Agency (EMA) and MHRA. Previously she was Head of Cellular, Developmental and Physiological Sciences at the Wellcome Trust and most recently an Industrial Strategy Challenge Fund Director at UK Research and Innovation.Regulatory Chapter Lead & Regulatory Science Lead , Roche Pharmaceuticals
Gracy Crane is a cancer biologist by training with a Master in Biomedical Research and a Ph.D. in Cancer Biology. She has also completed post-doctoral training fellowships at Oxford University (UK) and Massachusetts Institute of Technology (USA).
She has over 12 years of years of experience in the pharmaceutical industry, in varying roles including medical and scientific affairs, clinical development, health outcomes research and real world data. For the past 5 years, she has worked on leading the real world evidence strategy for molecules within the rare cancer space as part of the global Data Science team of the personalized health care department at Roche. Currently, she is the RWD policy lead and Chapter Lead within the Global Regulatory Science team at Roche. She has authored many publications on this topic and has presented in many international conferences.
Gracy is also part of a number of external steering/working groups including the ISPOR RWD transparency Initiative (https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative), the CIOMs working group on RWD/E guidelines, and the Duke Margolis RWE Collaborative, and a member of EFPIA IEGU. She is also a co-author on the HARPER work: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5507
Director, Medicines and Healthcare products Regulatory Agency’s (MHRA)
Puja Myles is Director of the Medicines and Healthcare products Regulatory Agency’s (MHRA) specialist real world data research service, the Clinical Practice Research Datalink (CPRD). She is a public health specialist and prior to joining CPRD, was a public health academic at the University of Nottingham, UK. She is a fellow of the Faculty of Public Health (UK), a senior fellow of the Higher Education Academy (UK) and has a doctorate in epidemiology.